GlassScriptPhysician profile
Robert F Maddux
NPI 1831319359
$1,781.68
in general payments reported to CMS, 2019-2025
14 companies · $69.34 in 2025
The $69.34 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $133 · 2021: $429 · 2022: $254 · 2023: $178 · 2024: $121 · 2025: $69.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $575.54 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $195.43 | 2019-2023 | Ingrezza |
| Lundbeck LLC | $188.94 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $187.40 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $136.00 | 2020-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Avanir Pharmaceuticals, INC. | $118.40 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $100.73 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $69.76 | 2019-2021 | |
| Shire North American Group INC | $56.77 | 2019 | |
| Ironshore Pharmaceuticals INC. | $49.09 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $44.70 | 2022-2024 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $20.45 | 2025 | Cobenfy |
| Indivior INC. | $20.11 | 2023 | Perseris |
| Greenwich Biosciences, INC. | $18.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Maddux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.